1 / 15

Innovative Access Models for Diagnostics (Pathology testing) Mukul Bagga

Innovative Access Models for Diagnostics (Pathology testing) Mukul Bagga Quest D iagnostics India . *. * American Clinical Lab association 2007 The value of Clinical Lab services. Diagnostics (Pathology testing) contributes only 2% of the Health care market .

neylan
Download Presentation

Innovative Access Models for Diagnostics (Pathology testing) Mukul Bagga

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Innovative Access Models for Diagnostics (Pathology testing) Mukul Bagga Quest Diagnostics India Confidential – Do not copy or distribute

  2. * * American Clinical Lab association 2007 The value of Clinical Lab services Confidential – Do not copy or distribute

  3. Diagnostics (Pathology testing) contributes only 2% of the Health care market Confidential – Do not copy or distribute

  4. Innovative Market Access models for Diagnostics ( Pathology Services) Confidential – Do not copy or distribute

  5. Innovative Market Access models for Diagnostics ( Pathology Services) Confidential – Do not copy or distribute

  6. Cervical Cancer Screening Program • Tamil Nadu Health Systems Project Experience • Annual Mortality : 74000 deaths : 27% of the world • Implemented screening protocol Developed by expert committee, wetted by TATA memorial Institute of Cancer, wetted and approved further by WHO • Visual Inspection with Acetic Acid & Lugol’s Iodine (VIA/VILI) under magnification • Simple, easy-to-learn approach • Minimal infrastructure required • High sensitivity - low proportion of false negatives. • Test results available immediately. • Decreased loss to follow up as the results read and interpreted then and there • Any trained health worker can do it and it does not require that only a Doctor or a Specialist should do the test • 19 lakh women (10%of Rural population) screened from Jan’13-Sep13 • Positivity rate is approx 5% vs reported 12-20% Confidential – Do not copy or distribute

  7. Innovative Market Access models for Diagnostics ( Pathology Services) Confidential – Do not copy or distribute

  8. TB testing in the IPAQT programe • Burden of disease : 40% of population are carriers and 10% are culture positive • Gap between Smear positive and culture positive cases : • Smear : Low sensitivity • Culture : Gold standard but 3 weeks to confirm • Growing menace of MDRTB • Advent of GeneXpert technology through the IPAQT consortium supported by Clinton foundation • Subsidised machine and reagents and market price controlled • How widely is it utilized ? • 10% of all cases Confidential – Do not copy or distribute

  9. Innovative Market Access models for Diagnostics ( Pathology Services) Confidential – Do not copy or distribute

  10. Innovative Market Access models for Diagnostics ( Pathology Services) Confidential – Do not copy or distribute

  11. Companion Diagnostics • Advent of personalised medicine is expected to reduce the cost of healthcare by improving response rates to medicines • Medicines would be prescribed based on certain biomarkers detected through diagnostic tests • Alk mutation for selection of Crizotinib for treatment of Lung cancer • EGFR mutation for usage of Erlotinib for Lung cancer • Her2 New mutation for usage of Trastuzumab for treatment of Breast cancer • Due to self pay nature of Indian market : usage of such companion diagnostics was limited • Pharma companies provide coupons for free testing to Doctors who pass this onto patients for providing them access to such treatments • Approx 20% patients expected to benefit from this out of a total of 500,000 cancer patients treated per year Confidential – Do not copy or distribute

  12. Innovative Market Access models for Diagnostics ( Pathology Services) Confidential – Do not copy or distribute

  13. Innovative Market Access models for Diagnostics ( Pathology Services) Confidential – Do not copy or distribute

  14. Second opinion through digital pathology Creates high-quality, high resolution images Review by organ- specific experts Accurate diagnosis • State of Art digital System • Organ-specific Histopathologists with experience • of more than 10 million annual biopsies globally • Extensive range of IHC markers validated • (like ER/PR, HER-2 NEU, BRCA-1,2, EBV)

  15. Thank You! Confidential – Do not copy or distribute

More Related